Increasing frequency beyond the weekly schedule risks unpredictable drug accumulation, injection site irritation, nausea or other GI side effects from inappropriate dosing intervals, and data gapsthis dosing pattern hasn't been studied in clinical trials
The active substance in Wegovy, semaglutide, is a 'GLP-1 receptor agonist'
Glucagon-like peptide-1 (GLP-1) receptor agonists aka the -tides, GLP analogs, incretin mimetics *The FDA has approved the use of -glutides to reduce the risk of major cardiovascular events (myocardial infarction, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
doi:10.1016/s0015-0282(03)00657-5
Look no further than NAD Plus Immunity Booster
Fructans (garlic, onion, wheat) no standard enzyme blend, Flatter Me included, breaks these down